Journal article
Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report
Clinical rheumatology, v 26(2), pp 251-253
01 Feb 2007
PMID: 16328092
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
We report a now 13-year-old male with trisomy 21, hypothyroidism, and insulin-dependent diabetes who developed acute hemiplegia due to the antiphospholipid antibody syndrome (APS) at age four. The risks of long-term anticoagulation were initially considered to be high; hence, he was treated with monthly infusions of intravenous immunoglobulin (IVIG) at 2 g/kg for 2 years and then every other month for 7 years. Antiphospholipid antibodies were no longer detectable within 6 months and have continued to be negative. There was no clinical deterioration or further changes on magnetic resonance arteriography over 7 years. IVIG may be an alternative therapeutic choice for children with APS who are not candidates for conventional anticoagulation.
Metrics
Details
- Title
- Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report
- Creators
- B. Arabshahi - St. Christopher's Hospital for ChildrenE. D. Thompson - St. Christopher's Hospital for ChildrenE. M. Smergel - St. Christopher's Hospital for ChildrenD. P. Goldsmith - St. Christopher's Hospital for Children
- Publication Details
- Clinical rheumatology, v 26(2), pp 251-253
- Publisher
- Springer Nature
- Number of pages
- 3
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000243032300023
- Scopus ID
- 2-s2.0-33845864422
- Other Identifier
- 991019168403204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Rheumatology